Bcr-Abl
Les inhibiteurs de Bcr-Abl sont des thérapies ciblées qui inhibent la protéine de fusion Bcr-Abl, formée à la suite de la translocation du chromosome Philadelphie et moteur de la leucémie myéloïde chronique (LMC). Cette protéine influence également l'angiogenèse, contribuant à la progression tumorale. Les inhibiteurs de Bcr-Abl sont cruciaux dans le traitement de la LMC et sont explorés pour leur potentiel à inhiber l'angiogenèse dans divers cancers. Chez CymitQuimica, nous offrons des inhibiteurs de Bcr-Abl de haute qualité pour soutenir vos recherches en biologie du cancer, angiogenèse et thérapies ciblées.
102 produits trouvés pour "Bcr-Abl"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
AKE-72
CAS :<p>AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.</p>Formule :C30H29F3N6ODegré de pureté :98.3%Couleur et forme :SoildMasse moléculaire :546.59N-Desmethyl imatinib
CAS :<p>N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.</p>Formule :C28H29N7ODegré de pureté :98.60%Couleur et forme :Off-White To Pale-Yellow SolidMasse moléculaire :479.58Imatinib Mesylate
CAS :<p>Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,</p>Formule :C29H31N7O·CH4SO3Degré de pureté :98% - >99.99%Couleur et forme :White Crystalline PowderMasse moléculaire :589.71Dasatinib
CAS :<p>Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive.</p>Formule :C22H26ClN7O2SDegré de pureté :99.59% - 99.86%Couleur et forme :Pale-Yellow SolidMasse moléculaire :488.01Nilotinib
CAS :<p>Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.</p>Formule :C28H22F3N7ODegré de pureté :99.89% - >99.99%Couleur et forme :Off-White SolidMasse moléculaire :529.52Lyn-IN-1
CAS :<p>Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and Lyn</p>Formule :C30H31F3N8ODegré de pureté :97% - 98.02%Couleur et forme :SolidMasse moléculaire :576.62Bosutinib
CAS :<p>Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.</p>Formule :C26H29Cl2N5O3Degré de pureté :98.98% - 99.9%Couleur et forme :Yellowish-Orange Or Pink To Brownish Solid Solid PowderMasse moléculaire :530.45Dasatinib monohydrate
CAS :<p>Dasatinib monohydrate, an oral SRC-kinase inhibitor, counters imatinib-resistant chronic myeloid leukemia.</p>Formule :C22H28ClN7O3SDegré de pureté :99.68% - >99.99%Couleur et forme :SolidMasse moléculaire :506.03LXH254
CAS :<p>LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.</p>Formule :C25H25F3N4O4Degré de pureté :98.3% - 99.92%Couleur et forme :SolidMasse moléculaire :502.49SNIPER(ABL)-058
CAS :<p>SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL protein</p>Formule :C62H75N11O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1150.39ML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Formule :C47H53BrCl2N10O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1052.86AD57
CAS :<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formule :C22H20F3N7ODegré de pureté :99.05%Couleur et forme :SoildMasse moléculaire :455.44FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Couleur et forme :LiquidSNIPER(ABL)-039
CAS :<p>SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 of</p>Formule :C54H68ClN11O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1114.77SNIPER(ABL)-020
<p>SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.</p>Formule :C44H59ClN10O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :923.52cSRC/BCR-ABL-IN-1
<p>cSRC/BCR-ABL-IN-1 (compound 21b) is a potent inhibitor of Bcr-Abl and C-Src, with IC50 values of 56.2 nM and 101 nM, respectively. It exhibits cytotoxicity.</p>Formule :C29H31Cl2N5O4Couleur et forme :SolidMasse moléculaire :584.494DPH
CAS :<p>DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.</p>Formule :C18H13FN4O2Degré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :336.32c-ABL-IN-5
<p>C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability,</p>Formule :C19H17F2N3ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :341.35SNIPER(ABL)-047
<p>SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,</p>Formule :C67H82F3N11O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1274.5SIAIS100
<p>SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.</p>Formule :C44H50ClF2N9O5SCouleur et forme :SolidMasse moléculaire :890.44Tyrosine kinase-IN-8
<p>Tyrosine kinase-IN-8 (compound 4e) is a BCR‐ABL1 tyrosine kinase inhibitor (TKI) exhibiting antiproliferative activity against the chronic myeloid leukemia (CML) cell line K562, with a CC50 of 0.8 µM. Tyrosine kinase-IN-8 is applicable for research in chronic leukemia.</p>Formule :C31H21F2N7O2Masse moléculaire :561.17248SNIPER(ABL)-019
<p>SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting a</p>Formule :C60H77ClN12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1177.85BCR-ABL-IN-9
<p>BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.</p>Formule :C22H20N4O3Couleur et forme :SolidMasse moléculaire :388.42SNIPER(ABL)-044
<p>SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving a</p>Formule :C51H64F3N9O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1020.17FGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Formule :C28H26Cl2N4O3Couleur et forme :SolidMasse moléculaire :537.44SNIPER(ABL)-013
<p>SNIPER(ABL)-013, a compound that links GNF5 (ABL inhibitor) with Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of</p>Formule :C42H52F3N7O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :839.9SNIPER(ABL)-015
<p>SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5</p>Formule :C58H70F3N9O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1094.23SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Formule :C68H84N12O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1213.47Abl Cytosolic Substrate
CAS :<p>Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).</p>Formule :C64H101N15O16Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1336.58PROTAC BCR-ABL1 ligand 1
CAS :<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Formule :C17H12F3N3O2Couleur et forme :SoildMasse moléculaire :347.29Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Couleur et forme :Odour SolidImatinib impurities3
CAS :<p>Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.</p>Formule :C24H20ClN5ODegré de pureté :98.63%Couleur et forme :SolidMasse moléculaire :429.9cSRC/BCR-ABL1-IN-1
<p>cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.</p>Formule :C24H27ClN6O4Couleur et forme :SolidMasse moléculaire :498.96SIAIS178
CAS :<p>SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).</p>Formule :C50H62ClN11O6S2Degré de pureté :98.07%Couleur et forme :SolidMasse moléculaire :1012.68BCR-ABL-IN-10
<p>BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).</p>Formule :C24H22N4O5SCouleur et forme :SolidMasse moléculaire :478.52SNIPER(ABL)-049
<p>SNIPER(ABL)-049, a compound that conjugates Imatinib (ABL inhibitor) with Bestatin (IAP ligand) through a linker, effectively reduces BCR-ABL protein levels,</p>Formule :C52H66N10O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :959.14SNIPER(ABL)-033
CAS :<p>SNIPER(ABL)-033, a compound that conjugates HG-7-85-01 (ABL inhibitor) to a LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein</p>Formule :C61H73F3N10O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1211.42SNIPER(ABL)-024
CAS :<p>SNIPER(ABL)-024, a compound that conjugates GNF5 (ABL inhibitor) to an LCL161 derivative (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels,</p>Formule :C52H61F3N8O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1031.15Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Couleur et forme :Odour SolidPROTAC BCR-ABL Degrader-1
<p>PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and</p>Formule :C43H40N10O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :792.84BCR-ABL-IN-3
CAS :<p>BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.</p>Formule :C20H17ClF2N4O3SCouleur et forme :SolidMasse moléculaire :466.89Asciminib hydrochloride
CAS :<p>Asciminib (ABL001) hydrochloride is a selective and potent mutant BCR-ABL1 inhibitor that inhibits Ba/F3 cell growth (IC50: 0.25 nM).</p>Formule :C20H19Cl2F2N5O3Couleur et forme :SolidMasse moléculaire :486.3Rebastinib
CAS :<p>DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,</p>Formule :C30H28FN7O3Degré de pureté :99.53% - 99.79%Couleur et forme :SolidMasse moléculaire :553.59GNF-7
CAS :<p>GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.</p>Formule :C28H24F3N7O2Degré de pureté :97.05% - 99.7%Couleur et forme :SolidMasse moléculaire :547.53AT9283
CAS :<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formule :C19H23N7O2Degré de pureté :99.83% - 99.98%Couleur et forme :SolidMasse moléculaire :381.43GMB-475
CAS :<p>GMB-475, a PROTAC-based BCR-ABL1 inhibitor, tackles drug resistance by promoting VHL-mediated degradation.</p>Formule :C43H46F3N7O7SDegré de pureté :98.78% - >99.99%Couleur et forme :SolidMasse moléculaire :861.93Olverembatinib
CAS :<p>Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).</p>Formule :C29H27F3N6ODegré de pureté :98.53% - >99.99%Couleur et forme :SolidMasse moléculaire :532.56Nocodazole
CAS :<p>Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.</p>Formule :C14H11N3O3SDegré de pureté :98% - 99.91%Couleur et forme :Physical Description White Powder (Ntp 1992)Masse moléculaire :301.32Olverembatinib dimesylate
CAS :<p>Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).</p>Formule :C29H27F3N6O·2CH4O3SDegré de pureté :97.66% - >99.99%Couleur et forme :SolidMasse moléculaire :724.77Dasatinib N-oxide
CAS :<p>Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.</p>Formule :C22H26ClN7O3SDegré de pureté :98.54% - 99.94%Couleur et forme :SolidMasse moléculaire :504
